Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H26N2O3 |
| Molecular Weight | 426.508 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cc1c(c2cccc3c2n1[C@]([H])(CN4CCOCC4)CO3)C(=O)c5cccc6ccccc65
InChI
InChIKey=HQVHOQAKMCMIIM-HXUWFJFHSA-N
InChI=1S/C27H26N2O3/c1-18-25(27(30)22-9-4-7-19-6-2-3-8-21(19)22)23-10-5-11-24-26(23)29(18)20(17-32-24)16-28-12-14-31-15-13-28/h2-11,20H,12-17H2,1H3/t20-/m1/s1
| Molecular Formula | C27H26N2O3 |
| Molecular Weight | 426.508 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
WIN 55212-2 is the synthetic cannabimimetic compound. It is a potent aminoalkylindole cannabinoid receptor agonist. WIN 55,212-2 increases expression of anti-oxidant Cu/Zn SOD and is able to prevent inflammation induced by Aβ1-42 in cultured astrocytes. It exerts neuroprotective and anti-inflammatory actions against Aβ damage through both CB₁ and CB₂ receptors. WIN 55212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. In the clinical trial, it was revealed that WIN 55212-2, applied topically, decreases the intraocular pressure of human glaucoma resistant to conventional therapies within the first 30 min.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL218 |
93.0 nM [Ki] | ||
Target ID: WP195 |
|||
Target ID: CHEMBL253 |
3.3 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. | 1995 Sep |
|
| Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. | 1996 Jun 7 |
|
| Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. | 1996 Sep |
|
| N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. | 2002 Dec |
|
| The heritability of antinociception: common pharmacogenetic mediation of five neurochemically distinct analgesics. | 2003 Feb |
|
| Long-term effects on cortical glutamate release induced by prenatal exposure to the cannabinoid receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone: an in vivo microdialysis study in the awake rat. | 2004 |
|
| Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. | 2004 Jan |
|
| Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens. | 2009 Jun |
|
| Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine. | 2009 Mar 10 |
|
| Cannabinoid CB1 and cholecystokinin CCK2 receptors modulate, in an opposing way, electrically evoked [3H]GABA efflux from rat cerebral cortex cell cultures: possible relevance for cortical GABA transmission and anxiety. | 2009 May |
|
| Endocannabinoids suppress excitatory synaptic transmission to dorsal raphe serotonin neurons through the activation of presynaptic CB1 receptors. | 2009 Oct |
Patents
Sample Use Guides
ChIP assays were performed to evaluate whether R(+)WIN 55,212-2 could affect the binding of the NF-kB subunit, p65, to the ICAM-1 and IL-8 promoters. 1321N1 astrocytoma were pre-treated with or without R(+)WIN 55,212-2 (20 uM) for 1 h prior to stimulation for a further 1 h in the absence or presence of IL-1 (10 ng/ml). p65 was absent at the promoters in unstimulated 1321N1 cells, but after 1-h stimulation with IL-1, p65 was detected at both promoters.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 11:41:49 UTC 2021
by
admin
on
Sat Jun 26 11:41:49 UTC 2021
|
| Record UNII |
5H31GI9502
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB13950
Created by
admin on Sat Jun 26 11:41:49 UTC 2021 , Edited by admin on Sat Jun 26 11:41:49 UTC 2021
|
PRIMARY | |||
|
5H31GI9502
Created by
admin on Sat Jun 26 11:41:49 UTC 2021 , Edited by admin on Sat Jun 26 11:41:49 UTC 2021
|
PRIMARY | |||
|
131543-22-1
Created by
admin on Sat Jun 26 11:41:49 UTC 2021 , Edited by admin on Sat Jun 26 11:41:49 UTC 2021
|
PRIMARY | |||
|
5311501
Created by
admin on Sat Jun 26 11:41:49 UTC 2021 , Edited by admin on Sat Jun 26 11:41:49 UTC 2021
|
PRIMARY | |||
|
131513-18-3
Created by
admin on Sat Jun 26 11:41:49 UTC 2021 , Edited by admin on Sat Jun 26 11:41:49 UTC 2021
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
WIN 55,212-2
Created by
admin on Sat Jun 26 11:41:49 UTC 2021 , Edited by admin on Sat Jun 26 11:41:49 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
